Pabau Engage inbox

Pabau Engage is here: every patient conversation in one inbox.

Learn more
Book a demo Book a demo
☰
CCSD Code

CCSD code Q2230 – Bilateral laparoscopic oophorectomy and salpingectomy


Code Definition

Q2230 is the CCSD code for bilateral laparoscopic oophorectomy and salpingectomy as a sole procedure. A biopsy of the omentum, peritoneum or a lymph node may be included. UK private medical insurers use it to identify keyhole removal of both ovaries and both fallopian tubes.

Q2231 covers the same operation on one side only. When another surgical procedure is performed in the same session, a different or combined CCSD code applies instead.

Group
14 Female reproductive organs
Category
14.1 Uterus/Adnexa
Subcategory
Bilateral laparoscopic oophorectomy and salpingectomy
Billable
No
Code also known as
bilateral BSO, laparoscopic BSO, bilateral adnexal removal, bilateral adnexectomy, bilateral salpingo-oophorectomy
Save time. Improve accuracy. Get paid faster.
Automate coding with Pabau

Let Pabau's smart automation suggest the right codes, reduce claim denials, and keep your practice compliant—effortlessly.

  • AI-powered code suggestions
  • Real-time compliance checks
  • Faster claims, fewer denials
Why practices choose Pabau
Save hours every week

Automate repetitive tasks and focus on what matters most—your patients.

Improve accuracy

Reduce coding errors and ensure compliance with the latest regulations.

Get paid faster

Clean claims, fewer denials, and faster reimbursements.

Grow with confidence

Powerful insights and reporting to help your practice thrive.

HIPAA compliant SOC 2 certified GDPR-compliant Trusted by 4,000+ clinics worldwide

Key takeaways

Key takeaways

CCSD code Q2230 covers laparoscopic removal of both ovaries and both fallopian tubes, billed as the sole procedure.

A biopsy of the omentum, peritoneum or a lymph node at the same sitting is part of Q2230, not a second code.

Q2231 is the unilateral equivalent. Use it when only one side is operated on, never Q2230.

UK insurers deny Q2230 claims most often for a breach of the sole procedure rule or a missing bilateral statement.

Pabau, the practice software we build, ties the CCSD code, the UK ICD-10 diagnosis and the pre-authorisation number to the operative record before submission.

CCSD code Q2230: Definition and procedure scope

CCSD code Q2230 describes laparoscopic oophorectomy and salpingectomy on both sides, performed as a sole procedure. A biopsy of the omentum, peritoneum or a lymph node may be included. Removing the uterus on its own through the vagina, with no laparoscope, is billed under CCSD code Q0800 instead.

The official descriptor, as printed in National Friendly’s schedule of fees, reads: Laparoscopic oophorectomy and salpingectomy, +/– biopsy eg. omentum, peritoneum, lymph node (as sole procedure) – bilateral.

CCSD (Clinical Coding & Schedule Development) is the procedure schedule UK private medical insurers use to identify surgery on a claim. Bupa, AXA Health, Aviva and Vitality maintain it, and Cigna, WPA, Healix and others use it too. It applies across England, Wales, Scotland and Northern Ireland.

Three elements of the descriptor need careful attention at billing time:

  • Bilateral: both ovaries and both fallopian tubes must be removed. If the operative report documents removal on one side only, Q2231 applies, not Q2230.
  • +/– biopsy: a biopsy of the omentum, peritoneum or a lymph node is an optional part of this single code. When one is taken at the same sitting, it is included within Q2230 and is not billed as an additional code.
  • As sole procedure: Q2230 is not billed alongside other CCSD surgical codes from the same operative session. This is the descriptor’s most consequential restriction and the reason behind the most common claim denials.

Q2230 sits in CCSD chapter 14 (Female reproductive organs), under sub-chapter 14.1 Uterus/Adnexa. The CCSD Technical Guide (October 2025) sets out the chapter structure and the business rules that govern unbundling. The same sub-chapter holds fertility-sparing cancer surgery on the cervix, such as radical trachelectomy under Q0712. Chapter 14 also holds code Q2080, for ventro-suspension of the uterus by an open or laparoscopic route.

What the procedure involves: Bilateral laparoscopic oophorectomy and salpingectomy

Coders need to know the operative steps, because the operative report must reflect each element the descriptor covers. A coder who does not know what bilateral adnexal removal looks like laparoscopically cannot tell whether the documentation is complete.

The procedure follows this sequence:

  1. Port placement: three to four laparoscopic ports are inserted, typically one umbilical port plus two or three in the lower quadrants.
  2. Bilateral adnexal identification: both ovaries and both fallopian tubes are identified, and their appearance and any abnormality are recorded.
  3. Bilateral excision: each ovary and tube is excised by coagulating and dividing the infundibulopelvic ligament and broad ligament on that side. The operative report must state bilateral explicitly rather than describe each side in a way that could be miscounted.
  4. Optional biopsy: where clinically indicated, samples are taken from the omentum, the peritoneum, or pelvic or para-aortic lymph nodes. Each biopsy site must be named in the operative note. If no biopsy is taken, the code is still Q2230.
  5. Specimen retrieval: the adnexal tissue is retrieved in an endobag or through an enlarged port site, and specimen identity is confirmed.
  6. Closure: the port sites are closed to the surgeon’s preference, with haemostasis documented.

Every biopsy site named in the note must match a specimen sent to pathology. A note that says “omental biopsy performed” with no matching pathology request is inconsistent. That can trigger an insurer query or a retrospective audit.

Clinical indications: When Q2230 applies

Q2230 suits a range of gynaecological conditions. The documented indication decides which UK ICD-10 code is paired on the claim, and it can affect whether the insurer pre-authorises the procedure.

  • Ovarian or tubal malignancy: bilateral adnexal removal for confirmed or suspected gynaecological cancer, often with omental and lymph node biopsies for staging. This is the indication most often associated with the biopsy element of Q2230.
  • Risk-reducing bilateral salpingo-oophorectomy (BSO) in BRCA carriers: NICE guideline CG164 recommends discussing this surgery with women who carry a BRCA1, BRCA2 or TP53 mutation. The Royal College of Obstetricians and Gynaecologists (RCOG) also publishes guidance on women with a genetic predisposition to gynaecological cancer. A biopsy is less common here, though peritoneal washings may still be taken.
  • Severe bilateral endometriosis: advanced pelvic endometriosis involving both adnexa, where bilateral adnexal removal is the definitive surgical option.
  • Benign bilateral adnexal pathology: large bilateral ovarian cysts, bilateral dermoids or other benign disease where the ovaries cannot be conserved.

The operative report must state the indication clearly, and it must agree with the UK ICD-10 code on the claim. An insurer reads a Q2230 claim paired with a benign cyst code differently from one paired with a malignancy code.

Pro Tip

Before you submit a Q2230 claim for a risk-reducing BSO, check the operative report. It should name the BRCA1 or BRCA2 mutation status and the reason for risk-reducing surgery. Insurers review prophylactic procedures more closely than cancer surgery.

Understanding the sole procedure restriction for CCSD code Q2230

The sole procedure restriction means Q2230 describes the operation only when bilateral adnexal removal is the one surgical procedure performed in that session. CCSD’s business rules put it plainly: a code marked “as sole procedure” should not be coded in addition to another procedure.

What this rule does and does not permit:

  • Covered within Q2230: steps intrinsic to the operation, such as peritoneal washings for cytology or a biopsy named in the descriptor. The anaesthetist’s fee is billed separately and is not affected by the sole procedure rule.
  • Not billed with Q2230: any other CCSD surgical code from the same session. That rules out a hysterectomy code, a cystoscopy code or a diagnostic laparoscopy code such as Q3900. When a second procedure is performed, a different or combined CCSD code usually describes the operation instead. Hysterectomy with removal of the omentum and adnexa for ovarian malignancy, for example, is Q0880.
  • Insurer-by-insurer variation: each insurer applies its own rules to combined sessions. Check with the patient’s insurer before you bill one.

If the plan pairs bilateral adnexal removal with another substantial procedure, agree the CCSD code with the billing team and the insurer before surgery. Settling it after the claim is submitted is slower and riskier.

Choosing the correct code means telling Q2230 apart from its unilateral twin. The table below compares the two.

CodeDescriptor (summary)LateralitySole procedureTypical use case
Q2230Laparoscopic oophorectomy and salpingectomy, +/– biopsyBilateral (both sides)YesOvarian malignancy, risk-reducing BSO, bilateral benign pathology
Q2231Laparoscopic oophorectomy and salpingectomy, +/– biopsyUnilateral (one side only)YesOne-sided adnexal pathology, with single-side removal confirmed in the operative report

Laterality, as documented in the operative report, decides the code. If the surgeon removed the ovary and tube on one side, Q2231 applies. If both sides were removed, Q2230 applies. Never select Q2230 when the report is unclear about whether both sides were addressed.

The approach matters as much as the laterality. The same operation through an abdominal incision moves to the open pair: Q2233 for both sides and Q2232 for one, as the grid below shows.

Decision grid for CCSD oophorectomy and salpingectomy codes as sole procedure
Approach and laterality together pick one of four sole procedure codes, and a second procedure rules all four out. Descriptors as listed in National Friendly’s October 2025 schedule of fees.

Check each descriptor against the current CCSD schedule before you submit, because CCSD reviews its codes periodically. Our library of CCSD procedure codes covers the rest of chapter 14.

UK ICD-10 diagnosis codes to pair with Q2230

Every Q2230 claim needs a paired diagnosis code from ICD-10, the WHO classification used in the UK. The code must reflect the documented indication, not a presumed or approximate diagnosis. The table lists the codes most often paired with each main indication.

UK ICD-10 codeDescriptionClinical indicationPre-authorisation likely?
C56Malignant neoplasm of ovaryOvarian cancer, for staging or curative resectionYes
Z40.0 with Z80.3 or Z80.4Prophylactic surgery for risk factors related to malignant neoplasms, with family history of breast or genital organ cancerRisk-reducing BSO in BRCA1/2 carriersYes, often with genetic counselling documentation
N80.1 / N80.2Endometriosis of ovary / of fallopian tubeSevere bilateral endometriosis requiring adnexal removalVaries by insurer and policy
D27Benign neoplasm of ovaryBilateral benign cysts or dermoidsVaries by insurer and policy

UK ICD-10 has no dedicated code for BRCA carrier status, so the prophylactic indication is usually shown through Z40.0 plus a family history code. Confirm each insurer’s coding expectations before you submit, as some ask for the genetic test result in the pre-authorisation request.

Documentation requirements for Q2230 claims

A clean Q2230 claim depends on an operative report that confirms each element of the code descriptor. Along with the sole procedure rule, missing documentation is one of the two leading causes of rejected claims.

The operative report must include:

  • An explicit bilateral statement: the report must say that the right and left ovary and fallopian tube were both removed. Describing each side in a separate note without a summary bilateral statement creates ambiguity.
  • The technique: a confirmed laparoscopic approach, with enough detail on ports and instruments to distinguish it from an open or robotic procedure.
  • Biopsy sites, if taken: each omental, peritoneal or lymph node biopsy must be named and must match a submitted pathology specimen.
  • The indication: it must match the UK ICD-10 code on the claim. A note that says “ovarian cancer staging” must be paired with a malignancy code, not a benign cyst code.
  • Surgeon and anaesthetist details: both clinicians’ names, insurer recognition numbers and roles must appear on the claim or the attached correspondence.

Structured patient records in a practice management system capture each part of the operative report, rather than relying on ad hoc dictation. If the report turns out to lack one of these elements after surgery, most insurers accept an addendum signed and dated by the operating surgeon.

Comprehensive EMR and patient record management in Pabau
Pabau’s patient record keeps the operative report, pathology references and diagnosis in one place. That lets you check a Q2230 claim against the notes before it goes out.

Pro Tip

Run five checks before you submit a Q2230 claim. Confirm bilateral removal in the operative report and name any biopsy sites. Match the indication to the UK ICD-10 code, attach the pre-authorisation number, and include both surgeon and anaesthetist details.

Pre-authorisation and insurer requirements

UK private medical insurers expect pre-authorisation for a planned procedure such as Q2230. The patient usually calls their insurer for an authorisation number before admission, and the practice quotes it on the claim. Requirements vary by insurer and by policy, so check them before each procedure.

A pre-authorisation request typically includes:

  • the referral and the consultant’s letter confirming the indication, the planned procedure and the hospital
  • supporting imaging reports, such as ultrasound, CT or MRI, where applicable
  • pathology or genetic test results for BRCA-related risk-reducing cases
  • the admission type (day case or inpatient) and the expected length of stay

When emergency surgery rules out pre-authorisation, contact the insurer as soon as practicable to ask about retrospective approval. Record the clinical urgency in the operative report, because the insurer will ask for it.

Who sets the fee for Q2230? Each insurer does

CCSD sets no fees. The code tells the insurer which operation was performed. Each insurer’s own schedule and the patient’s policy then decide what Q2230 pays the surgeon and the anaesthetist.

Look up the current figure in each insurer’s provider tools before you quote a patient, such as the Healix fee schedule. If your fee is above the insurer’s schedule, tell the patient about the shortfall in writing before surgery.

Common claim denials for Q2230 and how to avoid them

Bilateral laparoscopic oophorectomy and salpingectomy claims fail for a predictable set of reasons. The table below maps each denial to its fix.

Denial reasonWhat triggers itHow to prevent it
Sole procedure rule breachedQ2230 billed alongside another CCSD surgical code from the same sessionSubmit Q2230 as the only surgical code, and contact the insurer in advance if the plan includes another procedure
Bilateral not documentedThe operative report does not confirm that both sides were operated onInclude a bilateral statement in the operative summary, and ask the surgeon for an addendum if it is missing
Wrong code: unilateral procedure billed as bilateralQ2230 submitted when only one side was operated on (Q2231 applies)Check laterality in the operative report before choosing the code, and query the surgeon when it is unclear
Biopsy sites undocumentedA biopsy is implied by the record but not named in the operative reportName each biopsy site in the operative note and match it to the pathology specimen labels
Pre-authorisation missing or expiredA planned procedure submitted without a valid authorisation number, or after the authorisation lapsedQuote the authorisation number on the claim, and renew it if the surgery date moves beyond the approval window
UK ICD-10 mismatchThe diagnosis code does not match the stated indicationCross-check the UK ICD-10 code against the operative indication before submission

How to bill CCSD code Q2230 in Pabau

A clean Q2230 claim needs the right code, the right diagnosis and the right supporting details in place before submission. Pabau holds the CCSD code set and tracks pre-authorisation on the patient record, which removes several manual steps where errors creep in.

In Pabau’s medical billing software, a Q2230 claim for a UK private gynaecology practice moves through these steps:

Pabau billing screen fully integrated with the patient record
Pabau’s billing sits on the same record as the operative notes. The CCSD code, diagnosis and authorisation number on a Q2230 invoice therefore match the clinical record.
  1. Open the patient invoice: go to the patient’s encounter record and create an invoice for the operative episode.
  2. Select CCSD code Q2230: search for Q2230 in the procedure code field, and confirm the descriptor shown is the bilateral one before saving.
  3. Attach the UK ICD-10 diagnosis code: add the diagnosis, for example C56 for ovarian cancer, in the diagnosis field. It must match the indication in the clinical record.
  4. Enter the pre-authorisation number: add the insurer’s authorisation number in its field. If approval was retrospective, note the date and any reference correspondence.
  5. Confirm the bilateral statement and biopsy sites: check that the operative report is attached or referenced, with bilateral removal and any biopsy sites documented.
  6. Keep the anaesthetist’s claim separate: where the anaesthetist bills separately, make sure their fee is not duplicated on the surgical claim.
  7. Submit to the insurer: review the claim summary and confirm no other surgical code on the invoice breaches the sole procedure rule. Then submit it electronically, through Healthcode or directly to Bupa.

Practices running gynaecology lists at scale use templates that pre-fill the CCSD code, the usual diagnosis options and a documentation checklist for each procedure.

Linking the surgical documentation to the billing record leaves an auditable trail for insurer queries. Our guide to Bupa CCSD codes covers the wider framework, including Bupa-specific rules.

Manage CCSD billing without the guesswork

Pabau supports CCSD code entry, diagnosis code pairing, pre-authorisation tracking, and claim submission workflows for UK private gynaecology practices. See how it handles the complexity of codes like Q2230.

Pabau practice management dashboard for gynaecology billing

Conclusion

A Q2230 claim is won or lost in the operating theatre, when the surgeon writes the operative summary. If that summary says “bilateral”, names every biopsy site and states the indication, the coder has an easy job. Leave any of those out and no amount of careful coding will rescue the claim.

That makes the operative template the best place to protect your income from this code. Build the bilateral statement, the biopsy sites and the indication into it, and pair the indication with the matching UK ICD-10 code.

Book a demo to see how Pabau ties operative documentation, pre-authorisation and insurer claims into one workflow.

Continue your research

Continue your research

Coding a smaller gynaecology procedure from the same chapter? CCSD code Q2020 covers endometrial biopsy or aspiration and the documentation behind a clean claim.

Frequently asked questions

What does CCSD code Q2230 cover?

CCSD code Q2230 covers the laparoscopic removal of both ovaries and both fallopian tubes as a sole procedure. A biopsy of the omentum, peritoneum or a lymph node taken at the same sitting is included in the same code.

What is the difference between Q2230 and Q2231?

Q2230 covers the bilateral procedure, with both ovaries and both fallopian tubes removed. Q2231 covers the unilateral equivalent, on one side only. Laterality as documented in the operative report decides the code, so never use Q2230 when the report is unclear about both sides.

Can Q2230 be billed when other procedures are performed in the same session?

No. The sole procedure restriction means Q2230 is not combined with other CCSD surgical codes from the same session. When another procedure is performed, a different or combined CCSD code usually applies. Check with the patient’s insurer before the procedure date, not after the claim is rejected.

Who sets the fee for CCSD code Q2230?

Each insurer does. CCSD identifies the procedure but sets no fees, so Bupa, AXA Health, Aviva, Vitality and other insurers each pay Q2230 at their own schedule rate. Check the current figure in the insurer’s provider tools, and tell the patient in writing about any shortfall before surgery.

Is Q2230 used for risk-reducing bilateral salpingo-oophorectomy in BRCA carriers?

Yes. Risk-reducing bilateral salpingo-oophorectomy in BRCA1 and BRCA2 carriers is a recognised indication for Q2230, and NICE guideline CG164 recommends discussing it with these women. Insurers typically ask for genetic counselling documentation and a letter confirming the mutation status with the pre-authorisation request.

How is the anaesthetic billed alongside Q2230?

The anaesthetist bills separately, under the same CCSD procedure code, at the rate in the insurer’s anaesthetist schedule. The sole procedure restriction applies to surgical codes, so it does not affect the anaesthetist’s claim. Surgical assistant fees, where an insurer pays them, are also billed separately.

Avatar photo
Anja Dodevska
Content Writer

Anja Dodevska writes about healthcare, dermatology, and the day-to-day realities of running a medical practice for Pabau. She enjoys breaking down complex topics into clear, accessible content and has a soft spot for the often-overlooked aspects of clinic life. When she's not writing, she's exploring cafes, walking her dog, or spending time with friends and family.
×